Showing results (11-20 of 861) with videos related to
Sort By:
Pageof 87
Med (New York, N.Y.)|May 26, 2021
Increased Incidence of Venous Thromboembolism with Cancer ImmunotherapyJoanna Roopkumar, Shadi Swaidani, Ann S Kim, et al.Med (New York, N.Y.)|February 8, 2021
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodesEdwards Pradenas, Benjamin Trinité, Víctor Urrea, et al.Med (New York, N.Y.)|August 30, 2022
Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: A case seriesCynthia van Arkel, Martin Boeree, Cécile Magis-Escurra, et al.Med (New York, N.Y.)|August 25, 2022
Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockadeDouglas C Palmer, Beau R Webber, Yogin Patel, et al.Med (New York, N.Y.)|October 29, 2022
One size fits all: The story of SGLT2 inhibitors in heart failureSubodh Verma, Nitish K Dhingra, Deepak L Bhatt, et al.Med (New York, N.Y.)|February 1, 2025
HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 studyLijuan Hu, Xudong Wei, Weili Zhao, et al.Med (New York, N.Y.)|January 19, 2025
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trialHuayi Li, Yu Xu, Xiaofei Jiao, et al.Med (New York, N.Y.)|January 17, 2025
Immune-cell signatures of persistent inflammation, immunosuppression, and catabolism syndrome after sepsisXing-Feng Sun, Wen-Chen Luo, Shao-Qiang Huang, et al.Med (New York, N.Y.)|January 11, 2025
ALIGNing the treatment of IgA nephropathy: Reducing proteinuria with endothelin A receptor inhibitionLisa WillcocksMed (New York, N.Y.)|December 31, 2024
Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension studyRavi Savarirayan, Melita Irving, William R Wilcox, et al.Pageof 87